Polyclonal Antibody to Glial Cell Line Derived Neurotrophic Factor Receptor Alpha 1 (GFRa1)
Code | Size | Price |
---|
PAL548Hu01-20ul | 20ul | £93.00 |
Quantity:
PAL548Hu01-100ul | 100ul | £175.00 |
Quantity:
PAL548Hu01-200ul | 200ul | £237.00 |
Quantity:
PAL548Hu01-1ml | 1ml | £547.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
GDNFR; GDNFRA; GFR-ALPHA-1; RET1L; RETL1; TRNR1; GDNF family receptor alpha-1; TGF-beta-related neurotrophic factor receptor 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Glial Cell Line Derived Neurotrophic Factor Receptor Alpha 1
Reactivity:
Mu;Ra;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Glial Cell Line Derived Neurotrophic Factor Receptor Alpha 1 (GFRa1) | RPL548Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||